<DOC>
	<DOC>NCT00655252</DOC>
	<brief_summary>This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.</brief_summary>
	<brief_title>Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion criteria: ≥ 18 years old; metastatic renal cancer, intolerant of or failed sunitinib and/or sorafenib Adequate bone marrow function, liver function, renal function Adequate birth control Exclusion criteria: Previously received RAD001 or other mTOR inhibitors, known hypersensitivity to rapamycin, chronic systemic treatment with corticosteroids or immunosuppressive agents (prednisone ≤ 20 mg/day for adrenal insufficiency OK Topical or inhaled steroids OK) Active bleeding Uncontrolled angina, CHF, heart attack ≤ 6 months, uncontrolled diabetes Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Expanded access</keyword>
	<keyword>metastatic renal cell cancer</keyword>
	<keyword>progression despite VEGF receptors</keyword>
</DOC>